Market Cap 804.47M
Revenue (ttm) 0.00
Net Income (ttm) -206.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,808,600
Avg Vol 2,443,096
Day's Range N/A - N/A
Shares Out 163.84M
Stochastic %K 17%
Beta 1.22
Analysts Strong Sell
Price Target $13.55

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
keywestbitcoin
keywestbitcoin May. 20 at 4:25 PM
$ANNX I buy with the insiders, not worried about uninformed shorts!
0 · Reply
Lightening_strikes
Lightening_strikes May. 20 at 3:58 PM
$ANNX who’s unloading. ?
0 · Reply
Thomas105
Thomas105 May. 20 at 10:32 AM
1 · Reply
Biotech80
Biotech80 May. 20 at 10:30 AM
0 · Reply
BioRich
BioRich May. 20 at 6:59 AM
$ADMA $ALT $ARDX $LXRX $ANNX (Sorry, using this is a placeholder to see how these track over time from today.)
1 · Reply
Consti22
Consti22 May. 19 at 1:41 PM
1 · Reply
Lightening_strikes
Lightening_strikes May. 18 at 8:51 PM
$ANNX annihilated on nothing Down 25% in one month off recent high
1 · Reply
Thomas105
Thomas105 May. 18 at 1:21 PM
$ANNX This guy is patting himself on the back. Well, at least he...
2 · Reply
Rickylinderman
Rickylinderman May. 16 at 12:25 AM
$ANNX puts printed thank you. Whew
0 · Reply
Lightening_strikes
Lightening_strikes May. 15 at 12:24 AM
$ANNX so this stock is up like r2k year to date but 50x the risk. Brilliant year in and out
1 · Reply
Latest News on ANNX
Annexon initiated with a Neutral at Goldman Sachs

2026-05-12T09:15:39.000Z - 9 days ago

Annexon initiated with a Neutral at Goldman Sachs


110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

May 11, 2026, 10:00 AM EDT - 9 days ago

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS


Annexon reports Q1 EPS (23c), consensus (30c)

2026-05-07T21:46:09.000Z - 13 days ago

Annexon reports Q1 EPS (23c), consensus (30c)


Annexon Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 14 days ago

Annexon Quarterly report: Q1 2026


Annexon Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 14 days ago

Annexon Earnings release: Q1 2026


Annexon Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 24 days ago

Annexon Proxy statement: Proxy filing


Annexon Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 24 days ago

Annexon Proxy statement: Proxy filing


Annexon Slides: Corporate presentation

Apr 27, 2026, 7:00 AM EDT - 24 days ago

Annexon Slides: Corporate presentation


Annexon Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 weeks ago

Annexon Proxy statement: Proxy filing


Annexon files automatic mixed securities shelf

2026-03-31T10:20:07.000Z - 7 weeks ago

Annexon files automatic mixed securities shelf


Annexon reports Q4 EPS (28c), consensus (32c)

2026-03-30T20:18:52.000Z - 7 weeks ago

Annexon reports Q4 EPS (28c), consensus (32c)


Annexon Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 7 weeks ago

Annexon Earnings release: Q4 2025


Annexon Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 7 weeks ago

Annexon Annual report: Q4 2025


Annexon Transcript: KOL event

Mar 18, 2026, 2:00 PM EDT - 2 months ago

Annexon Transcript: KOL event


Annexon Slides: KOL event

Mar 18, 2026, 2:00 PM EDT - 2 months ago

Annexon Slides: KOL event


Annexon Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:50 AM EST - 2 months ago

Annexon Transcript: TD Cowen 46th Annual Health Care Conference


Annexon Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 4 months ago

Annexon Slides: 44th Annual J.P. Morgan Healthcare Conference


Annexon highlights its 2026 strategic priorities

2026-01-12T12:39:27.000Z - 4 months ago

Annexon highlights its 2026 strategic priorities


Annexon submits MAA to EMA for tanruprubart

2026-01-08T13:05:13.000Z - 4 months ago

Annexon submits MAA to EMA for tanruprubart


Annexon initiated with a Buy at Chardan

2025-12-23T09:35:20.000Z - 5 months ago

Annexon initiated with a Buy at Chardan


Annexon initiated with a Buy at Clear Street

2025-12-01T21:20:32.000Z - 6 months ago

Annexon initiated with a Buy at Clear Street


Annexon price target raised to $27 from $14 at Wells Fargo

2025-11-19T11:35:39.000Z - 6 months ago

Annexon price target raised to $27 from $14 at Wells Fargo


Annexon Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:30 AM EST - 6 months ago

Annexon Transcript: Jefferies London Healthcare Conference 2025


Annexon price target lowered to $8 from $9 at BofA

2025-11-17T14:30:07.000Z - 6 months ago

Annexon price target lowered to $8 from $9 at BofA


Annexon price target lowered to $8 from $9 at BofA

2025-11-16T15:55:10.000Z - 6 months ago

Annexon price target lowered to $8 from $9 at BofA


Annexon 25.1M share Spot Secondary priced at $2.60

2025-11-13T04:25:17.000Z - 6 months ago

Annexon 25.1M share Spot Secondary priced at $2.60


Annexon announces $75M common stock, warrants offering

2025-11-12T21:23:07.000Z - 6 months ago

Annexon announces $75M common stock, warrants offering


Annexon reports Q3 EPS (37c), consensus (34c)

2025-11-10T21:40:18.000Z - 6 months ago

Annexon reports Q3 EPS (37c), consensus (34c)


Annexon Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Annexon Earnings release: Q3 2025


Annexon Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Annexon Quarterly report: Q3 2025


Annexon participates in a conference call with JPMorgan

2025-09-15T14:40:07.000Z - 8 months ago

Annexon participates in a conference call with JPMorgan


Annexon Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Annexon Transcript: Cantor Global Healthcare Conference 2025


Annexon reports Q2 EPS (34c), consensus (36c)

2025-08-14T20:36:16.000Z - 9 months ago

Annexon reports Q2 EPS (34c), consensus (36c)


Annexon reports Q2 EPS (34c), consensus (36c)

2025-08-14T20:15:45.000Z - 9 months ago

Annexon reports Q2 EPS (34c), consensus (36c)


Annexon Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Annexon Earnings release: Q2 2025


Annexon Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Annexon Quarterly report: Q2 2025


Annexon completes enrollment in Phase 3 ARCHER II trial

2025-07-24T11:15:36.000Z - 10 months ago

Annexon completes enrollment in Phase 3 ARCHER II trial


Annexon tells Wells Fargo doctor tweet not factural

2025-07-10T17:50:08.000Z - 11 months ago

Annexon tells Wells Fargo doctor tweet not factural


Annexon Earnings release: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

Annexon Earnings release: Q1 2025


Annexon Quarterly report: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

Annexon Quarterly report: Q1 2025


Annexon Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Annexon Proxy statement: Proxy Filing


Annexon Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Annexon Proxy statement: Proxy Filing


Annexon Annual report: Q4 2024

Mar 3, 2025, 12:00 AM EST - 1 year ago

Annexon Annual report: Q4 2024


Annexon Slides: FY 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Annexon Slides: FY 2025


Annexon Transcript: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Transcript: Study Result


Annexon Press release: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Press release: Study Result


Annexon Slides: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Slides: Study Result


Annexon Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Annexon Quarterly report: Q3 2024


Annexon Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 9:30 AM EDT - 1 year ago

Annexon Transcript: 2024 Wells Fargo Healthcare Conference


Annexon Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Annexon Quarterly report: Q2 2024


Annexon Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Annexon Earnings release: Q2 2024


Annexon Registration statement: Registration Filing

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Annexon Registration statement: Registration Filing


Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 2 years ago

Annexon Announces Proposed Public Offering of Common Stock


Annexon Transcript: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Transcript: Study Update


Annexon Press release: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Press release: Study Update


Annexon Slides: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Slides: Study Update


Annexon Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 11:40 AM EDT - 2 years ago

Annexon Transcript: BofA Securities 2024 Health Care Conference


Annexon Quarterly report: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Annexon Quarterly report: Q1 2024


Annexon Earnings release: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Annexon Earnings release: Q1 2024


Annexon Slides: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Annexon Slides: Q1 2024


Annexon Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Annexon Proxy statement: Proxy Filing


Annexon Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Annexon Proxy statement: Proxy Filing


keywestbitcoin
keywestbitcoin May. 20 at 4:25 PM
$ANNX I buy with the insiders, not worried about uninformed shorts!
0 · Reply
Lightening_strikes
Lightening_strikes May. 20 at 3:58 PM
$ANNX who’s unloading. ?
0 · Reply
Thomas105
Thomas105 May. 20 at 10:32 AM
1 · Reply
Biotech80
Biotech80 May. 20 at 10:30 AM
0 · Reply
BioRich
BioRich May. 20 at 6:59 AM
$ADMA $ALT $ARDX $LXRX $ANNX (Sorry, using this is a placeholder to see how these track over time from today.)
1 · Reply
Consti22
Consti22 May. 19 at 1:41 PM
1 · Reply
Lightening_strikes
Lightening_strikes May. 18 at 8:51 PM
$ANNX annihilated on nothing Down 25% in one month off recent high
1 · Reply
Thomas105
Thomas105 May. 18 at 1:21 PM
$ANNX This guy is patting himself on the back. Well, at least he...
2 · Reply
Rickylinderman
Rickylinderman May. 16 at 12:25 AM
$ANNX puts printed thank you. Whew
0 · Reply
Lightening_strikes
Lightening_strikes May. 15 at 12:24 AM
$ANNX so this stock is up like r2k year to date but 50x the risk. Brilliant year in and out
1 · Reply
Biotech80
Biotech80 May. 14 at 12:19 PM
$ANNX Personally waiting for a better entry closer to the US filing on Annexon, Inc.. Timeline is starting to get more defined: * EU filing already in * US submission expected this year (GBS) * Q4 GA Phase 3 readout still the major catalyst Right now it still feels like a pre-catalyst positioning phase, so I’d rather see a pullback or clearer entry around the filing event rather than chasing momentum here. GBS is the near-term de-risking step, but GA is where the real re-rating comes if the data hits.
1 · Reply
MarketBeat
MarketBeat May. 14 at 8:06 AM
https://marketbeat.com/a/8653487/ $ANNX Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
0 · Reply
Lightening_strikes
Lightening_strikes May. 13 at 7:15 PM
$ANNX said they have term sheets for GBs Europe But not taking them now Why? Bank of America today
0 · Reply
makingdoughfromoptions
makingdoughfromoptions May. 13 at 4:19 PM
$ANNX Until news of some sort hits expect $5-6 ish range. That news would be FDA BLA filing for GBS, EMA progression through clock stops, EMA/CHMP approval and lastly, and biggest one, top line Phase 3 data for GA that is positive, like 40%+ reduction in 15 letter loss. There you have it. Need to wait some months.
1 · Reply
Thomas105
Thomas105 May. 13 at 8:34 AM
$ANNX another conference today We need higher price targets to move
1 · Reply
Rickylinderman
Rickylinderman May. 12 at 1:56 PM
$ANNX your daily red. Whew
0 · Reply
Lightening_strikes
Lightening_strikes May. 12 at 11:08 AM
$ANNX The firm questions the likelihood of Phase 3 success, citing lack of statistical significance on lesion growth rate in Phase 2 data and sham underperformance on best corrected visual acuity in Phase 2. Goldman Sachs estimates peak sales for vonaprument at $1.5 billion.
2 · Reply
Lightening_strikes
Lightening_strikes May. 12 at 10:53 AM
$ANNX goldman initiates at neutral? Ugh
0 · Reply
Lightening_strikes
Lightening_strikes May. 8 at 3:33 PM
$ANNX can’t hold any gains
0 · Reply
makingdoughfromoptions
makingdoughfromoptions May. 8 at 1:53 PM
$ANNX Q1 report yesterday, after hours, and Pres. Doug Love confirmed all we already knew....everything is on track. I do not expect the GA data for P3 to reach the 72% improvement of P2, but ANYTHING close will lead to approval as first in class to help prevent GA vision loss. And 8 million people worldwide have it. Monthly shots. You do the math, but it works out to being bought out by BP. For a fu** of a lot more than current SP. By a factor of ten.
0 · Reply
Sly15
Sly15 May. 8 at 1:35 PM
$ANNX Good remark in earnings release. States they have Real World Evidence data positively affecting GBS. To my recollection, with the FDA they only needed a little bit of this data, like showing 1 week. I don't know how much they have, but during his Conference with Needham, the order of events for the year has FDA BLM submission next. This places that before the Archer II study data during 4th Q. So sometime between now and then. I'm thinking they may be sooner rather than later, depends on when they can get the FDA meeting scheduled.
1 · Reply